|
| Press Releases |
|
 |
|
| Friday, June 21, 2024 |
|
|
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City |
| Eisai Co., Ltd. announced today that the company has achieved the pre-set performance indicators in FY2023 for the dementia examination project in Bunkyo City, Tokyo, which the company has been commissioned to conduct in order to raise awareness of dementia and promote early detection, and will continue the commission for this project in FY2024. more info >> |
|
| Monday, June 10, 2024 |
|
|
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
|
エーザイとバイオジェン、早期アルツハイマー病治療剤「レケンビ(R)」の静注維持投与に関する生物製剤承認一部変更申請が米国FDAにより受理 |
| エーザイ株式会社とバイオジェン・インクは、このたび、ヒト化抗ヒト可溶性アミロイドβ（Aβ）凝集体モノクローナル抗体「レケンビ(R)」（一般名：レカネマブ）について、静注（IV）維持投与に関する生物製剤承認一部変更申請（sBLA）が米国食品医薬品局（FDA）に受理されたことをお知らせします。 more info >> |
|
| Monday, June 3, 2024 |
|
|
Eisai Named to List of The Time 100 Most Influential Companies |
| TIME reveals the TIME100 Most Influential Companies list, highlighting companies making an extraordinary impact around the world. more info >> |
|
|
Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform |
| Eisai Co., Ltd. announced today that the company decided to strengthen and continue its venture investment business, which launched in 2019, with the aim of discovering innovative technologies and services, supporting venture businesses with such technologies and partnering with those businesses in the future, so as to accelerate drug discovery innovation and the establishment of the ecosystem platform. more info >> |
|
|
エーザイ、TIME 誌による「最も影響力のある 100 社（TIME100 MOST INFLUENTIAL COMPANIES）」に選定 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、米国 TIME誌が選出する「TIME100 Most Influential Companies of 2024」に選定されたことをお知らせします。 more info >> |
|
|
エーザイ、創薬イノベーションおよびエコシステム プラットフォーム構築の加速に向けたベンチャー投資事業を強化 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、創薬イノベーションおよびエコシステム プラットフォーム構築の加速に向け、革新的技術やサービスの発掘とそれを有するベンチャー企業の支援、将来的な提携を目的とし、2019 年に開始したベンチャー投資事業を強化し、継続することを決定しましたのでお知らせします。 more info >> |
|
| Tuesday, May 28, 2024 |
|
|
LEQEMBI (lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Food and Drug Safety (MFDS) in South Korea has approved humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (lecanemab) for treatment in adult patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD (early AD). more info >> |
|
| Thursday, May 23, 2024 |
|
|
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024 |
| Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4. more info >> |
|
| Wednesday, May 22, 2024 |
|
|
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan |
| Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac group announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate, "MTX"), in Japan. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Hola Prime Establishes Industry's First Dedicated Risk Compliance Team
Dec 30, 2024 21:00: JST
|
|
|
Atlas Lithium Accelerates Production Readiness with Key Executive Appointments
Dec 30, 2024 20:09 HKT/SGT
|
|
|
World's first high-standard negative-pressure isolation ward built with MiC technology completes historical mission
Dec 30, 2024 20:04 HKT/SGT
|
|
|
Hola Prime Establishes Industry's First Dedicated Risk Compliance Team
Dec 30, 2024 20:00 HKT/SGT
|
|
|
中國營養品行業品牌商紐曼思公佈於香港主板上市計劃
Dec 30, 2024 19:19 HKT/SGT
|
|
|
中国营养品行业品牌商纽曼思公布于香港主板上市计划
Dec 30, 2024 18:46 HKT/SGT
|
|
|
全球首个组装合成可快速建造高规格负压隔离病房完成历史任务
Dec 30, 2024 18:10 HKT/SGT
|
|
|
全球首個組裝合成可快速建造高規格負壓隔離病房完成歷史任務
Dec 30, 2024 17:43 HKT/SGT
|
|
|
順豐控股：把握物流行業發展紅利 以人為本打造新質生產力
Dec 30, 2024 12:22 HKT/SGT
|
|
|
顺丰控股：把握物流行业发展红利 以人为本打造新质生产力
Dec 30, 2024 12:14 HKT/SGT
|
|
|
The Bilingual Book Company Launches New, Innovative Bilingual Audiobook App
Dec 27, 2024 22:30 HKT/SGT
|
|
|
Annual Surge of 37% in Legal and Compliance Job Roles while overall hiring drops 6% in Singapore: foundit Insights Tracker
Dec 27, 2024 15:20 HKT/SGT
|
|
|
Gruelling Challenge Awaits TGR In Saudi Arabia
Dec 27, 2024 15:20 JST
|
|
|
The General Incorporated Association Generative AI Japan Announces the Winners of the Japan Generative AI Award 2024
Dec 27, 2024 11:00 JST
|
|
|
MHI Included in "World Index" of Dow Jones Sustainability Index for Second Consecutive Year
Dec 27, 2024 9:36 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
